A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...
For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback